Danger of co-administration ferric carboxymaltose and denosumab: hypophosphatemia
Both denosumab-induced hypocalcemia and ferric carboxymaltose infusion-related hypophosphatemia have been extensively documented. There are significant risks associated with combining ferric carboxymaltose parenteral infusions and denosumab, including ...
Aysun Seker, Nurdan Senturk Durmus
doaj +1 more source
Recurrent Severe Hypophosphatemia Following Intravenous Ferric Carboxymaltose Infusion: A Case Report. [PDF]
Enchill LA +4 more
europepmc +1 more source
Refeeding Hypophosphatemia Among Critically Ill Surgical Patients: A Prospective Analysis of Incidence, Risk Factors, and Clinical Outcomes. [PDF]
Talih T +7 more
europepmc +1 more source
Burosumab use in fibroblast growth factor-23-mediated hypophosphatemia in McCune-Albright syndrome/fibrous dysplasia. [PDF]
Alsayed Hasan M, Al Mukaddam M.
europepmc +1 more source
Eating disorder-related electrolyte abnormalities and adverse outcomes: A systematic review and meta-analysis. [PDF]
Fremont D +20 more
europepmc +1 more source
X-Linked Hypophosphatemia Caused by a New Partial Insertion of LINE-1 in the <i>PHEX</i> Gene. [PDF]
Li D +5 more
europepmc +1 more source
Burosumab treatment in an adult with FGF23-mediated hypophosphatemia due to cutaneous skeletal hypophosphatemia syndrome. [PDF]
Tosi LL +5 more
europepmc +1 more source
ELECTROHEALTH study: prevalence and prognostic significance of mild hypophosphatemia in older adults. [PDF]
Fratangelo L, Dotto E, D'Amelio P.
europepmc +1 more source
X-linked hypophosphatemia and spinal cord compression: a systematic review and illustrative case. [PDF]
Czarnetzki C +8 more
europepmc +1 more source

